Financials Genelux Corporation

Equities

GNLX

US36870H1032

Biotechnology & Medical Research

Market Closed - Nasdaq 20:59:51 30/05/2024 BST 5-day change 1st Jan Change
2.65 USD -5.36% Intraday chart for Genelux Corporation -42.39% -81.08%

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 374.3 93.63 - -
Enterprise Value (EV) 1 374.3 92.45 88.57 93.63
P/E ratio -12.1 x -2.71 x -2.36 x -2.6 x
Yield - - - -
Capitalization / Revenue 2,202 x 23,407 x - 3.28 x
EV / Revenue 2,202 x 23,111 x - 3.28 x
EV / EBITDA - - - -
EV / FCF -17.6 x -3.85 x -2.33 x -3.47 x
FCF Yield -5.69% -26% -42.9% -28.8%
Price to Book - - - -
Nbr of stocks (in thousands) 26,718 33,438 - -
Reference price 2 14.01 2.800 2.800 2.800
Announcement Date 29/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 11.07 0.17 0.004 - 28.55
EBITDA - - - - - -
EBIT 1 - -3.013 -24.16 -25.19 -35.37 -36.43
Operating Margin - -27.22% -14,214.71% -629,693.75% - -127.6%
Earnings before Tax (EBT) 1 - -4.107 -28.3 -28.49 -35.27 -35.88
Net income 1 -16.38 -5.207 -28.3 -28.49 -35.27 -35.88
Net margin - -47.05% -16,645.29% -712,137.5% - -125.68%
EPS 2 -0.6000 -0.2100 -1.160 -1.035 -1.187 -1.075
Free Cash Flow 1 - - -21.3 -24 -38 -27
FCF margin - - -12,529.41% -600,000% - -94.57%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 24/06/22 29/03/23 29/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 0.17 - - - 0.008 - - - - -
EBITDA - - - - - - - - - -
EBIT 1 -6.462 -5.395 -5.307 -7.001 -8.115 -5.831 -6.024 -6.196 -6.1 -6.1
Operating Margin -3,801.18% - - - -101,437.5% - - - - -
Earnings before Tax (EBT) 1 -10.36 -5.821 -5.345 -6.767 -7.85 -6.938 -7.124 -7.367 -6.1 -6.1
Net income 1 -10.36 -5.821 -5.345 -6.767 -7.85 -6.938 -7.124 -7.367 -6.1 -6.1
Net margin -6,096.47% - - - -98,125% - - - - -
EPS 2 -0.5300 -0.2300 -0.2000 -0.2500 -0.2900 -0.2600 -0.2500 -0.2600 -0.2300 -0.2300
Dividend per Share - - - - - - - - - -
Announcement Date 15/05/23 14/08/23 14/11/23 29/03/24 09/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 - 24.5 - - - -
Net Cash position 1 - - - 1.18 5.06 -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - - -21.3 -24 -38 -27
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 - 0.05 1.03 0.7 1.2 3
Capex / Sales - 0.44% 602.94% 17,500% - 10.51%
Announcement Date 24/06/22 29/03/23 29/03/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.8 USD
Average target price
26 USD
Spread / Average Target
+828.57%
Consensus
  1. Stock Market
  2. Equities
  3. GNLX Stock
  4. Financials Genelux Corporation